Detalhe da pesquisa
1.
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Clin Infect Dis
; 76(9): 1646-1654, 2023 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36660819
2.
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Clin Infect Dis
; 77(10): 1423-1431, 2023 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37340869
3.
Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine.
Antimicrob Agents Chemother
; 66(3): e0170221, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34978890
4.
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Lancet
; 391(10123): 839-849, 2018 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29310899
5.
Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.
J Antimicrob Chemother
; 69(3): 728-34, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24155058
6.
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Lancet HIV
; 11(4): e211-e221, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538160
7.
Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study.
Open Forum Infect Dis
; 9(4): ofac067, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35350172
8.
Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2.
J Acquir Immune Defic Syndr
; 91(1): 73-78, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35551149
9.
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy.
AIDS
; 36(2): 195-203, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34652287
10.
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.
AIDS
; 36(2): 185-194, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34261093
11.
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
Lancet HIV
; 8(11): e668-e678, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34656207
12.
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.
AIDS
; 35(9): 1333-1342, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730748
13.
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Lancet HIV
; 8(4): e185-e196, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33794181
14.
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.
Open Forum Infect Dis
; 8(9): ofab439, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34557563
15.
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
J Acquir Immune Defic Syndr
; 85(3): 325-330, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32675772
16.
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
Lancet HIV
; 6(9): e576-e587, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31307948
17.
Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.
Antivir Ther
; 13(5): 655-61, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18771049
18.
Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers.
J Clin Pharmacol
; 48(3): 322-9, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18195053
19.
Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.
Pharmacotherapy
; 28(10): 1215-22, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18823217
20.
Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.
AIDS
; 32(4): 477-485, 2018 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29239893